1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Viatris Aims To Clear Up Investor ‘Disappointment’ After Breaking EBITDA Baseline

Company Also Reiterates $9bn Pre-Tax Proceeds Goal Via Divestments

 
• By Dean Rudge

Days after Viatris announced a landmark new direction – the divestment of its global biosimilars plus other assets – and its full-year 2021 earnings, company management spoke with a leading investment bank to clarify issues raised by Viatris’ shareholders.

Clock_Stock_Buyback
"Everything else" is competing with share buybacks • Source: Shutterstock

Viatris’ base business “has not changed” and “significant growth” is “possible,” the company insists, as it attributed another instance of shrinking EBITDA guidance for the year ahead to inflation and unfavorable exchange rates.

Company management made the disclosures during an institutional investors conference chaired by Raymond James’ Elliot Wilbur

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.